IMMUNOMODULATOR ACTIVITY OF MANGIFERIN FROM MANGO (MANGIFERA INDICA L.) IN CANCER: A SYSTEMATIC REVIEW

YACHI QURRATA AYUNI LUBAKISAR, FITRA FAUZIAH*, REZLIE BELLATASIE

Department of Pharmacology and Clinical Pharmacy, School of Pharmaceutical Science (STIFARM) Padang, West Sumatra, Indonesia,

Received: 17 May 2021, Revised and Accepted: 20 Aug 2021

ABSTRACT

Cancer is a disease that has a high prevalence worldwide. Cancer treatment requires high costs and various side effects that can affect the quality of life [1, 2]. Cancer ranks first cause of death in every country. In 2019, cancer was the leading cause of death under the age of 70. Based on the WHO report, in 2020, there be 19.3 million cancer cases and almost 10 million cancer deaths [3].

Currently, cancer treatment is experiencing rapid development with the hope of decreasing cancer mortality. One of the cancer treatments is immunotherapy [4]. Food and Drug Administration (FDA) approved immunotherapy drugs for cancer, namely vemurafenib, and ipilimumab. Vemurafenib works by inhibiting the b-rapidly accelerated fibrosarcoma (BRAF) protein, and the ipilimumab activates the immune system [5]. Immunomodulators are natural and adaptive compounds that can modulate the immune response. Immunomodulators are classified as adjuvants, suppressants and stimulants [6]. Stimulant-type immunomodulators response. Immunomodulators are classified as adjuvants, suppressants and stimulants [6]. Stimulant-type immunomodulators are used as food, cosmetics, and medicine [16]. It is found in tropical and subtropical regions and is one of the most popular fruits with low calories and high fiber [17, 18]. Mango contains polyphenol compounds [40-60%], a potentially therapeutic phytochemical compound [19]. Several studies have shown that the natural compound mangiferin has an anticancer activity where this compound can increase the sensitivity of cancer cells to anticancer drugs [26, 27]. Mangiferin also showed anti- inflammatory, antidiabetic, antioxidants, hypolipidemic, antiviral, immunomodulators, analgesics, and hepatoprotective activity [28-30]. Studies show that mangiferin has an immunomodulatory on T-cells and B-cells [31]. So far, there is no clinical evidence of side effects of mangiferin. This compound could be a candidate in drug development [32]. This article aims to summarize the immunomodulatory activity of mangiferin compounds in cancer.

INTRODUCTION

Cancer is a disease that has a high prevalence worldwide. Cancer treatment requires high costs and various side effects that can affect the quality of life [1, 2]. Cancer ranks first cause of death in every country. In 2019, cancer was the leading cause of death under the age of 70. Based on the WHO report, in 2020, there be 19.3 million cancer cases and almost 10 million cancer deaths [3].

In cancer, various immune responses are activated to avoid damage to the immune system [8]. Cancer cells will detect immune cells like T cells and macrophages, resulting in increased levels of proinflammatory cytokines that stimulate NF-κB activation and encourage proliferation and metastasis [9]. T cells play an essential role in immune and antitumor responses, while B cells help in producing antibodies [10]. T cell receptor (TCR) and CD3 gene increase TCR expression leading to faster tumor clearance [11, 12].

Many drugs derived from plants are sensitive and effective against tumor development, prolong patients’ survival time, and prevent side effects of chemotherapy [13–15]. One of them is mango (Mangifera indica L) which belongs to the Anacardiaceae family, widely used as food, cosmetics, and medicine [16]. It is found in tropical and subtropical regions and is one of the most popular fruits with low calories and high fiber [17, 18]. Mango contains polyphenol compounds [40-60%], a potentially therapeutic phytochemical compound [19]. Various studies had shown that polyphenols have anti-inflammatory and immunomodulatory [20, 21]. Polyphenol can also protect DNA from gamma-ray damage, which suggests that polyphenols act as radioprotection [22]. In mango, the most well-known compound is mangiferin [23].

Mangiferin compounds (1,3,6,7-tetrahydroxyflavonoid-C2-β-D-glucoside) (fig. 1) are the compounds derived from the leaves and skin of mango [24, 25]. Several studies have shown that the natural compound mangiferin has an anticancer activity where this compound can increase the sensitivity of cancer cells to anticancer drugs [26, 27]. Mangiferin also showed anti-inflammatory, antidiabetic, antioxidants, hypolipidemic, antiviral, immunomodulators, analgesics, and hepatoprotective activity [28-30]. Studies show that mangiferin has an immunomodulatory on T-cells and B-cells [31]. So far, there is no clinical evidence of side effects of mangiferin. This compound could be a candidate in drug development [32]. This article aims to summarize the immunomodulatory activity of mangiferin compounds in cancer.

Method of collecting data

A comprehensive search was carried out by collecting publications from several databases, i.e., Cochrane Library, Google Scholar, PubMed, ProQuest, ScienceDirect, and the Wiley Online Library. The keywords used were (cancer) AND (mangiferin) AND (immunomodulator). The literature used is an article published in the last ten years. Fig. 2 showed the flow chart of this systematic review.

**Fig. 1: Chemical structure of mangiferin**
Selection of articles
There are 2060 articles obtained from search results using keywords for articles published in the last ten years (0 articles from the Cochrane Library, 1416 articles from Google Scholar, two articles from PubMed, 555 articles from ProQuest, 32 articles from ScienceDirect, and 55 articles from the Wiley Online Library). After screening the title, abstract, and other variables, 285 articles met the inclusion criteria. After screening the full text, six articles meet the requirements, and it used in this review.

Mangiferin as NF-κB inhibitors
Natural compounds exhibit cytotoxic potential against cancer cells by causing apoptosis and suppressing Nuclear factor-kappa B (NF-κB) [33]. NF-κB is a transcription factor in the immune system with an anti-apoptotic effect, which works to increase the resistance of cancer cells [34]. Activation of NF-κB will increase the formation of TNF-α and IL-1β [35]. NF-κB is commonly used to promote tumor formation and regulate angiogenesis [36].

A study by du Plessis-Stoman et al. shows mangiferin act as NF-κB inhibitor and cause a reduction in NF-κB activation in cancer cells. Furthermore, the combination of oxaliplatin-mangiferin 10 µg mol/l increases IC50 in resistance cancer cells by modulating NF-κB. Mangiferin increased the percentage of dead cells with leakage of the cell membrane, with less necrosis occurred. These results suggest that mangiferin emphasizes cell death by apoptosis rather than necrosis [37,38] with oxaliplatin-mangiferin 10 µg mol/l [38]. Polyphenolic compounds such as mangiferin can affect signaling genes in the NF-κB pathway [39]. It inhibits not only NF-κB signaling but also inhibits phosphorylation of the mitogen-activated protein kinase signaling molecule (MAPK), including extracellular signal-regulated kinase (ERK1/2), jun-n terminal kinase (JNK), and p38 [40].

Mangiferin influences the regulation of β-catenin, EMT, MMP2, and MMP9
Administration of mangiferin 300 µM in ovarian clear cell endocervix (ES-2) produces an anti-MMP effect. It can inhibit the process of invasion, metastasis, angiogenesis in tumor cells. Mangiferin has also inhibited the β-catenin pathway, which plays an important role in anticancer activity [41]. β-catenin is a dual-function protein involved in regulating and coordinating cell adhesion and gene transcription, which plays an important role in the survival and regeneration of cells [42]. β-catenin modulates the proliferation of epithelial-mesenchymal transition cells (EMT) and matrix metalloproteinases (MMP). EMT is a process characterized by loss of adhesion with inhibition of closely related cell β-catenin, thereby leading to metastasis [43]. Meanwhile, MMP has the potential as a therapeutic target for cancer [44]. In the process of metastasis, MMP2 and MMP9 result in extracellular cleavage of matrix proteins in cancer cells by contributing to the epithelial to mesenchymal transition, which is the first step for cancer cells to become abnormal [45].

Mangiferin induces cytotoxicity by regulating LDH, NO, and ROS
The administration of 70 µM mangiferin toxic on rhabdomyosarcoma (RD) cells by using the MTT method. The mangiferin-induced cell death in RD cells is determined by lactate dehydrogenase and nitric oxide, generating reactive oxygen species in mitochondrial membranes [46]. Lactate dehydrogenase (LDH) is an enzyme produced by the cytosol. The increase in this enzyme occurred when the cell membrane was damaged by cytotoxicity. Nitric oxide (NO) plays a role in cellular signaling, and in high concentrations, NO has a cytotoxic effect [47]. NO can regulate many physiological processes that cause damage to DNA, proteins, and lipid molecules, leading to apoptosis [48]. One of the NO targets for maintaining thiol status and modulation of cell proliferation is glutathione (GSH) [49]. Research shows that NO induce GSH to make cells sensitive to cytotoxicity [50]. GSH forms oxidation products due to mangiferin, which leads to reactive oxygen species (ROS) generation. ROS plays a vital role in inducing cancer cell apoptosis [51]. Administration of 0.5 µM mangiferin to Mia-PaCa2 cells showed a significant increase in ROS levels so that it could induce apoptosis in cancer cells [52].

Mangiferin inhibits the activation of classic macrophages
Polarized macrophages release a large number of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α),...
interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8). Proinflammatory cytokines play an important role in the immune system response. Excessive production of cytokines will cause tissue and cell damage to induce cancer cell death through the proliferation process. Studies show that the levels of TNF-α, IL-1β, IL-6, and IL-8 in THP-1 cells can be reduced by stimulating lipopolysaccharides/interferon-gamma (LPS/IFN-γ) [53]. Administration of mangiferin 100 and 200 µmol/l to human THP-1 cells can significantly increase TNF-α, IL-1β, IL-6, and IL-8 [54]. Mangiferin also plays a role in reducing interferon regulatory factor 5 (IRF5), an important factor in regulating classical macrophage activation [55]. Classical macrophage activation is required for normal protection in the immune response. Thus, mangiferin produces beneficial disease-fighting effects that have potential in cancer therapy [56].

![Fig. 3: Mangiferin mechanism to the immune system in cancer](image)

CONCLUSION

Mangiferin in mango (Mangifera indica L.) potential as candidates drug in cancer. The effect of mangiferin on the immune system can treat cancer through various mechanisms. It works to inhibit NF-κB, anti-MMP, cytosolic induction through LDH, NO, ROS regulation and inhibits the activation of classic macrophages. It can be developed in strategies for cancer therapy that threatens global public health.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally to the literature review, analysis, and interpretation part. The manuscript was written by Ms. Yachi Qurrata Ayuni. The final version was approved for publication by Mrs. Fitra Fauziah and Ms. Rezlie Bellatasie.

CONFLICTS OF INTERESTS

The authors declare no conflicts of interest.

REFERENCES

1. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, Jemal A. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457-80. doi: 10.3322/caac.21314, PMID 26375877.

2. Sakhi B, Fokou PV, Yamihe LRT, Tali BT, Adetunji CO, Rahavain A, Mudau FN, Martorell M, Setzer WN, Rodrigues CF, Martins N, Cho WC, Sharifi-Rad J. Phytochemicals in prostate cancer: from bioactive molecules to upcoming therapeutic agents. Nutrients. 2019;11(7):1-43. doi: 10.3390/nu11071483, PMID 31261861.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Issue Information. CA A Cancer J Clin. 2021;71(1):1-2. doi: 10.3322/caac.21617.

4. Fávaro WJ, Nunes OS, Seiva FRF, Nunes IS, Woolhiser LL, Durán N, Lenaerts AJ. Effects of P-MAPA immunomodulator on toll-like receptors and PD-1/PDL1 potential therapeutic strategies for infectious diseases and cancer. Infect Agent Cancer. 2012;7(1):14. doi: 10.1186/1750-9378-7-1, PMID 22709446.

5. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferruuci PF, Smylie M, Dammer R, Hill A, Hogg D, Haanen J, Carino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McCarthy G, Lebèche C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-56. doi: 10.1056/NEJMoa1709684, PMID 28979292.

6. Jantan I, Ahmad W, Bukhari SN. Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front Plant Sci. 2015;6:655. doi: 10.3389/fpls.2015.00655, PMID 26379683.

7. Chang CY, Liu JD, Wang CY, Chen WR, Lee YJ. The combination of radiotherapy and immunotherapy using grafted chitosan as an immunological stimulant. Biophotonics Immune Resp 2015(9324):1-5.

8. Shang HS, Chen CJ, Shih YL, Peng SF, Chen YL, Liu KC, Huang HC, Hsueh SC, Chen KW, Lu HF, Lee MH, Lee MZ, Lu KW. Mangiferin induces immune responses and evaluates the survival rate in WEHI-3 cell generated mouse leukemia in vivo. Environ Toxicol. 2020;36:77-85. doi: 10.1002/tox.20131, PMID 32889744.

9. Hoesel B, Schmid JA. The complexity of NF-kB signaling in inflammation and cancer. Mol Cancer. 2013;12:86. doi: 10.1186/1476-4598-12-86, PMID 23915189.

10. Song JH, Bae MY, Jang MG, Park Y, Song K, Choi G, Hyun JW, Lee HW, Chae S. Protective effect of mango (Mangifera indica L.) against UVB-induced skin aging in hairless mice. Photodermatol Photoimmunol Photomed. 2013;29(2):104-12. doi: 10.1002/tox.23013, PMID 23915189.

11. Ahmadi M, King JW, Xue SA, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ. CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 2015;118(13):3528-37. doi: 10.1182/blood-2015-04-346338, PMID 21750319.

12. Meawathana J. Immune-related adverse events from immune checkpoint inhibitors: a review of risk factors in clinical practice. Pharm Sci Asia. 2020;47(2):104-12. doi: 10.1038/s41376-020-0109-2, PMID 32232602.

13. Pugliese GM, Pugliese LM, Pugliese NM, Joan NM. Cancer: A molecular curse. Int J Curr Pharm Res. 2020;36:77-85. doi: 10.1002/tox.23013, PMID 24009794.

14. Vard intermediate and advanced melamine. N Engl J Med. 2017;377(14):1345-56. doi: 10.1056/NEJMoa1709684, PMID 28979292.
34. Anti-inflammatory effects in streptozotocin and high fat rational approach for controlling malignant progression. Front 1α and NFκB in cancer treatment: nano-mixed micellar systems. Drug Delivery Transl Res.

35. Using vitamin E-TPGS co-loaded self-assembled phospholipidic from mango (Mangifera indica) varieties. J Agric Food Chem.

19. Noratto GD, PMID 26255828. doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev. 2014;15(4):1639-42. doi: 10.7314/apjcp.2014.15.4.1639, PMID 25590732.

20. Du M, Wen G, Jin J, Chen Y, Cao J. Xu A. Mangiferin prevents the growth of gastric carcinoma by blocking the PI3K-Akt signalling pathway. Anticancer Drugs. 2018;29(2):167-75. doi: 10.1097/CAD.0000000000001537, PMID 29215373.

21. Sekiguchi Y, Mano H, Nakatani S, Shimizu J, Kataoka A, Ogura K, Kimura Y, Ebah M, Wada M. Mangiferin positively regulates osteoblast differentiation and suppresses osteoclast differentiation. Mol Med. 2017;16(2):1328-32. doi: 10.3892/nnmr.2017.6752, PMID 28627701.

22. Zheng Z, Lin C, Wang S, Wang P, Xu W, Ma W, et al. Suppressive activities of mangiferin on human epithelial ovarian cancer. Phytomedicine. 2020;76:. 153267. PMID 153267.

23. Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J. 2012;31(4):2714–36. doi: 10.1038/emboj.2012.150, PMID 22647142.

24. Cai Z, Cao Y, Luo Y, Hu H, Ling H. Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance. Clin Chim Acta. 2018;483:156-63. doi: 10.1016/j.cca.2018.04.033, PMID 29790449.

25. Li H, Huang J, Yang B, Xiang T, Yin X, Peng W, et al. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. Toxicol Appl Pharmacol. 2013;272(1):180-90. doi: 10.1016/j.taap.2013.05.011, PMID 23707762.

26. Cabo J, Jia Y, Lee J, Schindel P, Gilbert SM, Peden AA, Junutula JR, Prekrais R. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J Cell Sci. 2013;126(20):467-8. doi: 10.1242/jcs.126573, PMID 23902685.

27. Padma VV, Kalaiselvi P, Yuvaraj R, Rabeeth M. Mangiferin induces cell death against rhadomyosarcoma through sustained oxidative stress. Integr Med Res. 2015;4(2):66-75. doi: 10.1016/j.imr.2014.09.006, PMID 25864172.

28. Kamm A, Przychoden P, Kuban-Jankowska A, Jaczewic D, Babrowska AM, Nussberger S, et al, Wozniak M, Gorska-Ponikowska M. Nitric oxide and its derivatives in the cancer battlefield. Nitric Oxide-Biol Chem. 2019;93:102-14. doi: 10.1016/j.niox.2019.01.005, PMID 30410713.

29. Choudhari SK, Chauhan T, Bhag S, Gadball AR, Joshi V. Nitric oxide and cancer: Aa review. World J Surg Oncol. 2013;11:18. doi: 10.1186/1747-7185-11-18, PMID 23718886.

30. Aquilano K, Baldelli S, Cardaci S, Rottoli G, Ciriolo MR. Nitric oxide is the primary mediator of cytotoxicity induced by GSH depletion in neuronal cells. J Cell Sci. 2011;124(7):1043-54. doi: 10.1242/jcs.077149, PMID 21368390.

31. Dubey M, Nagar Koti S, Awasthi D, Singh AK, Chandra T, Kumaravale J, Barthwal MK, Dikshit M. Nitric oxide-mediated apoptosis of neutrophils through caspase-8 and caspase-3-dependent mechanism. Cell Death Dis. 2016;7(9):1-12e2348. doi: 10.1038/cddis.2016.248, PMID 27584786.

32. Liu GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44(5):479-96. doi: 10.1080/10715760903365575, PMID 20370557.

33. Yu L, Chen M, Zhang R, Jin J. Inhibition of cancer cell growth in gemcitabine-resistant pancreatic carcinoma by mangiferin phytochemicals involves induction of autophagy, endogenous ROS production, cell cycle disruption, mitochondrion-mediated apoptosis and suppression of cancer cell migration and invasion. J BUON. 2012;17(4):1581-6, PMID 23166812.
52. Park KR, Bryers JD. Effect of macrophage classical (M1) activation on implant-adherent macrophage interactions with Staphylococcus epidermidis: a murine in vitro model system. J Biomed Mater Res A. 2012;100(8):2045-53. doi: 10.1002/jbm.a.34087, PMID 22581669.

53. Wei Z, Yan L, Chen Y, Bao C, Daeng J, Deng J. Mangiferin inhibits classical macrophage activation via downregulating interferon regulatory factor 5 expression. Mol Med Rep. 2016;14(2):1091-8. doi: 10.3892/mmr.2016.5352, PMID 27277156.

54. Wang LX, Zhang SX, Wu HJ, Rong XL, Guo J. M2b macrophage polarization and its roles in diseases. J Leukoc Biol. 2019;106(2):345-58. doi: 10.1002/JLB.3RU1018-378RR, PMID 30576000.

55. Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, Mo S, et al, Tomlinson G, Kropf P, Noursadeghi M, Harrison TS. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated Cryptococcal meningitis. PLoS Pathog. 2015;11(4):1–18e1004754. doi: 10.1371/journal.ppat.1004754, PMID 25853653.

56. Huang Y, Gao J, Meng XM, Jiang GL, Yang YR, Li H, Liu J, Li J. Involvement of mitogen-activated protein kinase activation in cyclooxygenase-2 and transforming growth factor-β production in alveolar macrophage from chronic bronchitis rats. Immunopharmacol Immunotoxicol. 2011;33(4):645-51. doi: 10.3109/08923973.2011.557383, PMID 21428715.